Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04485013 · ClinicalTrials.gov registry record · Phase 1

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

A Phase 1 study of Cancer, sponsored by Tizona Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
240
Enrollment target
20
Study locations

NCT04485013: Recruiting Phase 1 study of Cancer, sponsored by Tizona Therapeutics.

NCT04485013 is a Phase 1 study of Cancer that is actively recruiting participants, run by Tizona Therapeutics. The registered enrollment target is 240 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04485013, a Phase 1 study of Cancer, is actively recruiting participants, sponsored by Tizona Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.

Conditions Studied

Cancer

Interventions

  • DRUG pembrolizumab
  • DRUG cetuximab
  • DRUG FOLFIRI
  • DRUG TTX-080

Study Locations (20)

Florida

  • Florida Cancer Specialists - Daytona Beach
  • Florida Cancer Specialists - Fleming Island
  • Ocala Oncology Center - Ocala
  • AdventHealth Research Institute - Orlando

California

  • University of Southern California - Los Angeles
  • Hoag Memorial Hospital - Newport Beach

Illinois

  • Illinois Cancer Specialists - Arlington Heights
  • University of Illinois - Chicago

Maryland

  • American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders - Bethesda
  • Maryland Oncology Hematology - Silver Spring

Arizona

  • Arizona Oncology Associates - Tucson

Colorado

  • Rocky Mountain Cancer Centers - Denver

Connecticut

  • Yale Cancer Center - New Haven

Delaware

  • Christiana Care Helen F. Graham Cancer Center - Newark

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2020-07-14
Est. Completion 2027-06-01
Phase Phase 1

Sponsor

Tizona Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04485013

The ClinicalTrials.gov registry entry for NCT04485013 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Tizona Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which pembrolizumab is the first listed.

NCT04485013 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT04485013 about?

NCT04485013 is a clinical study titled "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers". TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI pl...

What is the current status of trial NCT04485013?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2020-07-14. Estimated completion is 2027-06-01.

What conditions does trial NCT04485013 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT04485013?

The interventions under investigation include: pembrolizumab (DRUG), cetuximab (DRUG), FOLFIRI (DRUG), TTX-080 (DRUG).

Who is sponsoring clinical trial NCT04485013?

This trial is sponsored by Tizona Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04485013 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.